Nucleophosmin and cancer

Nature Reviews Cancer

Volumn 6, Issue 7, 2006, Pages 493-505

  Grisendi, Silvia ^a   Mecucci, Cristina ^b   Falini, Brunangelo ^b   Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b POLICLINICO MONTELUCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ARF PROTEIN; CASPASE; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLINE; DEOXYRIBONUCLEASE; DNA; DNA DIRECTED DNA POLYMERASE ALPHA; DNA DIRECTED RNA POLYMERASE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 2ALPHA; INTERNAL TRANSCRIBED SPACER; MESSENGER RNA; NERVE GROWTH FACTOR; NUCLEOPHOSMIN; POLO LIKE KINASE 1; PROTEIN KINASE R; PROTEIN MDM2; PROTEIN P53; RETINOIC ACID RECEPTOR; RIBOSOME RNA; RNA POLYMERASE II; SHORT HAIRPIN RNA; SMALL NUCLEOLAR RIBONUCLEOPROTEIN; SUMO 1 PROTEIN; TUMOR MARKER; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER GENETICS; CARCINOGENESIS; CELL PROLIFERATION; CENTROSOME; CHROMOSOME TRANSLOCATION; DNA REPAIR; GENE; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; MICROTUBULE ORGANIZING CENTER; MYELODYSPLASTIC SYNDROME; NONHUMAN; NPM1 GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTO ONCOGENE; REVIEW; RIBOSOME; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; NUCLEAR PROTEINS;

EID: 33745534443     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1885     Document Type: Review

References (146)

1. Feuerstein, N. & Mond, J. J. Identification of a prominent nuclear protein associated with proliferation of normal and malignant B cells. J. Immunol. 139, 1818-1822 (1987).
2. Schmidt-Zachmann, M. S., Hugle-Dorr, B. & Franke, W. W. A constitutive nucleolar protein identified as a member of the nucleoplasmin family. EMBO J. 6, 1881-1890 (1987).
3. Schmidt-Zachmann, M. S. & Franke, W. W. DNA cloning and amino acid sequence determination of a major constituent protein of mammalian nucleoli. Correspondence of the nucleoplasmin-related protein NO38 to mammalian protein B23. Chromosoma 96, 417-426 (1988).
4. Kang, Y. J., Olson, M. O., Busch, H. & Jones, C. Phosphorylation of acid-soluble proteins in isolated nucleoli of Novikoff hepatoma ascites cells. Effects of divalent cations. Nucleolar phosphoproteins of normal rat liver and Novikoff hepatoma ascites cells. J. Biol. Chem. 249, 5580-5585 (1974).
5. Kang, Y. J., Olson, M. O., Jones, C. & Busch, H. Nucleolar phosphoproteins of normal rat liver and Novikoff hepatoma ascites cells. Cancer Res. 35, 1470-1475 (1975).
6. Feuerstein, N., Chan, P. K. & Mond, J. J. Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23. Implication for the role of the nucleolus in early transduction of mitogenic signals. J. Biol. Chem. 263, 10608-10612 (1988).
7. Chan, W. Y. et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry 28, 1033-1039 (1989).
8. Grisendi, S. et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437, 147-153 (2005). Shows for the first time that disruption of NPM expression in vivo leads to embryonic lethality at mid-gestation. The total or partial loss of Npm1 gene function leads to centrosome amplification, aneuploidy and cancer susceptibility.
9. Colombo, E. et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol. Cell. Biol. 25, 8874-86 (2005).
10. Falini, B. et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352, 254-266 (2005). The first paper to identify the cytoplasmic dislocation of NPM and the mutation of exon 12 of the NPM1 gene as a hallmark of a large subgroup of AML (NPMc+ AML).
11. Borer, R. A., Lehner, C. F., Eppenberger, H. M. & Nigg, E. A. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 56, 379-390 (1989).
12. Yun, J. P. et al. Nucleophosmin/B23 is a proliferate shuttle protein associated with nuclear matrix. J. Cell Biochem. 90, 1140-1148 (2003).
13. Hingorani, K., Szebeni, A. & Olson, M. O. Mapping the functional domains of nucleolar protein B23. J. Biol. Chem. 275, 24451-24457 (2000). In vitro analysis of the functional features of the different NPM molecular domains.
14. Szebeni, A. & Olson, M. O. Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 8, 905-912 (1999).
15. Okuwaki, M., Matsumoto, K., Tsujimoto, M. & Nagata, K. Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett. 506, 272-276 (2001).
16. Swaminathan, V., Kishore, A. H., Febitha, K. K. & Kundu, T. K. Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Mol. Cell. Biol. 25, 7534-7545 (2005).
17. Chang, J. H. & Olson, M. O. Structure of the gene for rat nucleolar protein B23. J. Biol. Chem. 265, 18227-18233 (1990).
18. Wang, D., Umekawa, H. & Olson, M. O. Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells. Cell. Mol. Biol. Res. 39, 33-42 (1993).
19. Herrera, J. E., Correia, J. J., Jones, A. E. & Olson, M. O. Sedimentation analyses of the salt- and divalent metal ion-induced oligomerization of nucleolar protein B23. Biochemistry 35, 2668-2673 (1996).
20. Namboodiri, V. M., Akey, I. V., Schmidt-Zachmann, M. S., Head, J. F. & Akey, C. W. The structure and function of Xenopus NO38-core, a histone chaperone in the nucleolus. Structure 12, 2149-2160 (2004).
21. Wang, D. et al. The nucleic acid binding activity of nucleolar protein B23. 1 resides in its carboxyl-terminal end. Interaction of nucleolar phosphoprotein B23 with nucleic acids. J. Biol. Chem. 269, 30994-30998 (1994).
22. Okuwaki, M., Tsujimoto, M. & Nagata, K. The RNA binding activity of a ribosome biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-dependent kinase and by association with its subtype. Mol. Biol. Cell. 13, 2016-2030 (2002).
23. Savkur, R. S. & Olson, M. O. Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res. 26, 4508-4515 (1998).
24. 3 receptor that mediates the anti-apoptotic effects of NGF by inhibiting the DNA fragmentation activity of CAD.
25. Tanaka, M., Sasaki, H., Kino, I., Sugimura, T. & Terada, M. Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res. 52, 3372-3377 (1992).
26. Nozawa, Y., Van Belzen, N., Van der Made, A. C., Dinjens, W. N. & Bosman, F. T. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J. Pathol. 178, 48-52 (1996).
27. Shields, L. B. et al. Induction of immune responses to ovarian tumor antigens by multiparity. J. Soc. Gynecol. Investig. 4, 298-304 (1997).
28. Subong, E. N. et al. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 39, 298-304 (1999).
29. Tsui, K. H., Cheng, A. J., Chang, P. L., Pan, T. L. & Yung, B. Y. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 64, 839-844 (2004).
30. Skaar, T. C. et al. Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 67, 391-402 (1998).
31. Redner, R. L., Rush, E. A., Faas, S., Rudert, W. A. & Corey, S. J. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87, 882-886 (1996).
32. Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994).
33. Raimondi, S. C. et al. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. Leukemia 3, 42-47 (1989).
34. Yoneda-Kato, N. et al. The t(3;5)(q25. 1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 12, 265-275 (1996).
35. Olney, H. J. & Le Beau, M. M. in The Myelodysplastic Syndromes, Pathobiology and Clinical Management (ed. Bennet, J. M.) 89-120 (Marcel Dekker, New York, 2002).
36. Mendes-da-Silva, P., Moreira, A., Duro-da-Costa, J., Matias, D. & Monteiro, C. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol. Pathol. 53, 184-187 (2000).
37. Berger, R. et al. Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. Leukemia 20, 319-321 (2006).
38. Bischof, D., Pulford, K., Mason, D. Y. & Morris, S. W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell. Biol. 17, 2312-2325 (1997).
39. Feuerstein, N. & Randazzo, P. A. In vivo and in vitro phosphorylation studies of numatrin, a cell cycle regulated nuclear protein, in insulin-stimulated NIH 3T3 HIR cells. Exp. Cell Res. 194, 289-296 (1991).
40. Gubin, A. N., Njoroge, J. M., Bouffard, G. G. & Miller, J. L. Gene expression in proliferating human erythroid cells. Genomics 59, 168-177 (1999).
41. Dergunova, N. N. et al. A major nucleolar protein B23 as a marker of proliferation activity of human peripheral lymphocytes. Immunol. Lett. 83, 67-72 (2002).
42. Zeller, K. I. et al. Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J. Biol. Chem. 276, 48285-48291 (2001).
43. Boon, K. et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 20, 1383-93 (2001).
44. Takemura, M. et al. Nucleolar protein B23.1 binds to retinoblastoma protein and synergistically stimulates DNA polymerase α activity. J. Biochem. (Tokyo) 125, 904-909 (1999).
45. Hsu, C. Y. & Yung, B. Y. Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells. Oncogene 16, 915-923 (1998).
46. You, B. J. et al. Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch. Pharmacol. 360, 683-690 (1999).
47. Yung, B. Y. c-Myc-mediated expression of nucleophosmin/B23 decreases during retinoic acid-induced differentiation of human leukemia HL-60 cells. FEBS. Lett. 578, 211-216 (2004).
48. Jiang, P. S. & Yung, B. Y. Down-regulation of nucleophosmin/B23 mRNA delays the entry of cells into mitosis. Biochem. Biophys. Res. Commun. 257, 865-870 (1999).
49. Wu, H. L., Hsu, C. Y., Liu, W. H. & Yung, B. Y. Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleophosmin/B23 and telomerase activity. Int. J. Cancer 81, 923-929 (1999).
50. Hsu, C. Y. & Yung, B. Y. Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acid-induced differentiation and apoptosis. Int. J. Cancer 88, 392-400 (2000).
51. Brady, S. N., Yu, Y., Maggi, L. B., Jr. & Weber, J. D. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 24, 9327-9338 (2004).
52. Dumbar, T. S., Gentry, G. A. & Olson, M. O. Interaction of nucleolar phosphoprotein B23 with nucleic acids. Biochemistry 28, 9495-9501 (1989).
53. Prestayko, A. W., Klomp, G. R., Schmoll, D. J. & Busch, H. Comparison of proteins of ribosomal subunits and nucleolar preribosomal particles from Novikoff hepatoma ascites cells by two-dimensional polyacrylamide gel electrophoresis. Biochemistry 13, 1945-1951 (1974).
54. Olson, M. O., Wallace, M. O., Herrera, A. H., Marshall-Carlson, L. & Hunt, R. C. Preribosomal ribonucleoprotein particles are a major component of a nucleolar matrix fraction. Biochemistry 25, 484-491 (1986).
55. Herrera, J. E., Savkur, R. & Olson, M. O. The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res. 23, 3974-3979 (1995).
56. Itahana, K. et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12, 1151-1164 (2003). Downregulation of NPM expression affects the processing of pre-ribosomal RNA and induces cell death. ARF is proposed to promote the polyubiquitylation and degradation of NPM, a possible target of the ability of ARF to inhibit rRNA processing in a p53-independent manner.
57. Ruggero, D. & Pandolfi, P. P. Does the ribosome translate cancer? Nature Rev. Cancer 3, 179-192 (2003).
58. Boxer, L. M. & Dang, C. V. Translocations involving c-myc and c-myc function. Oncogene 20, 5595-5610 (2001).
59. Bertwistle, D., Sugimoto, M. & Sherr, C. J. Physical and functional interactions of the ARF tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 24, 985-996 (2004). Shows that a significant proportion of nucleolar ARF associates with NPM in high-molecular-weight complexes (2-5 MDa), where NPM regulates the ability of ARF to retard rRNA processing.
60. ARF. As ARF also prevents the proliferation of cells that lack p53, it is shown to be able to specifically retard the processing of ribosomal RNA precursors, an effect that requires neither p53 nor MDM2.
61. Lerch-Gaggl, A. et al. Pescadillo is essential for nucleolar assembly, ribosome biogenesis, and mammalian cell proliferation. J. Biol. Chem. 277, 45347-45355 (2002).
62. Ye, K. Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis. Cancer Biol. Ther. 4, 918-923 (2005).
63. Kondo, T. et al. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15, 1275-1281 (1997).
64. Wu, M. H., Chang, J. H. & Yung, B. Y. Resistance to UV-induced cell-killing in nucleophosmin/B23 over-expressed NIH 3T3 fibroblasts: enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/B23 over-expression. Carcinogenesis 23, 93-100 (2002).
65. Romeo, G. et al. IRF-1 as a negative regulator of cell proliferation. J. Interferon Cytokine Res. 22, 39-47 (2002).
66. Li, J., Zhang, X., Sejas, D. P., Bagby, G. C. & Pang, Q. Hypoxia-induced nucleophosmin protects cell death through inhibition of p53. J. Biol. Chem. 279, 41275-41279 (2004).
67. Barber, G. N. Host defense, viruses and apoptosis. Cell Death Differ. 8, 113-126 (2001).
68. Jagus, R., Joshi, B. & Barber, G. N. PKR, apoptosis and cancer. Int. J. Biochem. Cell Biol. 31, 123-138 (1999).
69. Pang, Q. et al. Nucleophosmin interacts with and inhibits the catalytic function of eukaryotic initiation factor 2 kinase PKR. J. Biol. Chem. 278, 41709-41717 (2003).
70. Li, J., Zhang, X., Sejas, D. P. & Pang, Q. Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. Leuk. Res. (2005).
71. Yung, B. Y., Busch, H. & Chan, P. K. Translocation of nucleolar phosphoprotein B23 (37 kDa/pl 5. 1) induced by selective inhibitors of ribosome synthesis. Biochim. Biophys. Acta 826, 167-173 (1985).
72. Yung, B. Y., Bor, A. M. & Chan, P. K. Short exposure to actinomycin D induces 'reversible' translocation of protein B23 as well as 'reversible' inhibition of cell growth and RNA synthesis in HeLa cells. Cancer Res. 50, 5987-5991 (1990).
73. Chan, P. K., Aldrich, M. B. & Yung, B. Y. Nucleolar protein B23 translocation after doxorubicin treatment in murine tumor cells. Cancer Res. 47, 3798-3801 (1987).
74. Bor, A. M., Chang, F. J. & Yung, B. Y. Phosphoprotein B23 translocation and modulation of actinomycin D and doxorubicin cytotoxicity by dipyridamole in HeLa cells. Int. J. Cancer 52, 658-663 (1992).
75. Chan, P. K. Characterization and cellular localization of nucleophosmin/B23 in HeLa cells treated with selected cytotoxic agents (studies of B23-translocation mechanism). Exp. Cell Res. 203, 174-181 (1992).
76. Wu, M. H., Chang, J. H., Chou, C. C. & Yung, B. Y. Involvement of nucleophosmin/B23 in the response of HeLa cells to UV irradiation. Int. J. Cancer 97, 297-305 (2002).
77. Kurki, S. et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5, 465-475 (2004).
78. Fankhauser, C., Izaurralde, E., Adachi, Y., Wingfield, P. & Laemmli, U. K. Specific complex of human immunodeficiency virus type 1 rev and nucleolar B23 proteins: dissociation by the Rev response element. Mol. Cell. Biol. 11, 2567-2575 (1991).
79. Li, Y. P. Protein B23 is an important human factor for the nucleolar localization of the human immunodeficiency virus protein Tat. J. Virol. 71, 4098-4102 (1997).
80. Miyazaki, Y. et al. The cytotoxicity of human immunodeficiency virus type 1 Rev: implications for its interaction with the nucleolar protein B23. Exp. Cell Res. 219, 93-101 (1995).
81. Huang, W. H., Yung, B. Y., Syu, W. J. & Lee, Y. H. The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens and modulates the hepatitis delta virus RNA replication. J. Biol. Chem. 276, 25166-25175 (2001).
82. Chan, H. J., Weng, J. J. & Yung, B. Y. Nucleophosmin/ B23-binding peptide inhibits tumor growth and up-regulates transcriptional activity of p53. Biochem. Biophys. Res. Commun. 333, 396-403 (2005).
83. Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J. & Bar-Sagi, D. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell. Biol. 1, 20-26 (1999).
84. Kamijo, T. et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997).
85. Bothner, B. et al. Defining the molecular basis of Arf and Hdm2 interactions. J. Mol. Biol. 314, 263-277 (2001).
86. Kuo, M. L., den Besten, W., Bertwistle, D., Roussel, M. F. & Sherr, C. J. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 18, 1862-1874 (2004). Shows that NPM, which binds to ARF with high stoichiometry, is able to retard ARF turnover. NPM is crucial for ARF stability, as ARF mutants that do not efficiently associate with NPM are unstable and functionally impaired.
87. Sherr, C. J. The INK4a/ARF network in tumour suppression. Nature Rev. Mol. Cell Biol. 2, 731-737 (2001).
88. Sherr, C. J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984-2991 (1998).
89. Korgaonkar, C. et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 25, 1258-1271 (2005).
90. Llanos, S., Clark, P. A., Rowe, J. & Peters, G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nature Cell. Biol. 3, 445-452 (2001).
91. Nakagawa, M., Kameoka, Y. & Suzuki, R. Nucleophosmin in acute myelogenous leukemia. N. Engl. J. Med. 352, 1819-1820; author reply 1819-1820 (2005).
92. Falini, B. et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc + AML. Blood 107, 4514-4523 (2006). Elucidates the molecular mechanism of altered traffic of NPM and its cytoplasmic accumulation in NPMc+ AML.
93. den Besten, W., Kuo, M. L., Williams, R. T. & Sherr, C. J. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 4, 1593-1598 (2005).
94. Colombo, E. et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 66, 3044-3050 (2006).
95. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
96. Oren, M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274, 36031-36034 (1999).
97. Rubbi, C. P. & Milner, J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22, 6068-6077 (2003). Shows that the nucleolus functions as a stress sensor that is responsible for the maintenance of low levels of p53 in proliferating cells.
98. Horn, H. F. & Vousden, K. H. Cancer: guarding the guardian? Nature 427, 110-111 (2004).
99. Pestov, D. G., Strezoska, Z. & Lau, L. F. Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. Mol. Cell. Biol. 21, 4246-4255 (2001).
100. Colombo, E., Marine, J. C., Danovi, D., Falini, B. & Pelicci, P. G. Nucleophosmin regulates the stability and transcriptional activity of p53. Nature Cell. Biol. 4, 529-533 (2002).
101. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
102. Wang, X. W. et al. GADD45 induction of a G2/M cell cycle checkpoint. Proc. Natl Acad. Sci. USA 96, 3706-3711 (1999).
103. Hollander, M. C. et al. Genomic instability in Gadd45a-deficient mice. Nature Genet. 23, 176-184 (1999).
104. Gao, H. et al. B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G2-M arrest. J. Biol. Chem. 280, 10988-10996 (2005).
105. Lee, S. Y. et al. A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-binding proteins in response to DNA double-strand breaks. Biochem. J. 388, 7-15 (2005).
106. Nigg, E. A. Mitotic kinases as regulators of cell division and its checkpoints. Nature Rev. Mol. Cell Biol. 2, 21-32 (2001).
107. Jiang, P. S., Chang, J. H. & Yung, B. Y. Different kinases phosphorylate nucleophosmin/B23 at different sites during G(2) and M phases of the cell cycle. Cancer Lett. 153, 151-160 (2000).
108. Okuda, M. et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103, 127-140 (2000). Identifies NPM as a substrate of the CDK2-cyclin E complex, and implicates it in the regulation of centrosome duplication in a cell-cycle-dependent manner.
109. Chan, P. K., Liu, Q. R. & Durban, E. The major phosphorylation site of nucleophosmin (B23) is phosphorylated by a nuclear kinase II. Biochem. J. 270, 549-552 (1990).
110. Peter, M., Nakagawa, J., Doree, M., Labbe, J. C. & Nigg, E. A. Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase. Cell 60, 791-801 (1990).
111. Scheer, U. & Weisenberger, D. The nucleolus. Curr. Opin. Cell Biol. 6, 354-359 (1994).
112. Hernandez-Verdun, D. & Gautier, T. The chromosome periphery during mitosis. Bioessays 16, 179-185 (1994).
113. Dundr, M., Misteli, T. & Olson, M. O. The dynamics of postmitotic reassembly of the nucleolus. J. Cell Biol. 150, 433-446 (2000).
114. Zatsepina, O. V. et al. The nucleolar phosphoprotein B23 redistributes in part to the spindle poles during mitosis. J. Cell Sci. 112 (Pt 4), 455-466 (1999).
115. Compton, D. A. & Cleveland, D. W. NuMA, a nuclear protein involved in mitosis and nuclear reformation. Curr. Opin. Cell Biol. 6, 343-346 (1994).
116. Yao, J. et al. Nek2A kinase regulates the localization of numatrin to centrosome in mitosis. FEBS Lett. 575, 112-118 (2004).
117. Zhang, H. et al. B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1. J. Biol. Chem. 279, 35726-35734 (2004).
118. Meraldi, P. & Nigg, E. A. The centrosome cycle. FEBS Lett. 521, 9-13 (2002).
119. Hinchcliffe, E. H., Li, C., Thompson, E. A., Maller, J. L. & Sluder, G. Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. Science 283, 851-854 (1999).
120. Fry, A. M., Schultz, S. J., Bartek, J. & Nigg, E. A. Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of Aspergillus nidulans. J. Biol. Chem. 270, 12899-12905 (1995).
121. Fry, A. M. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene 21, 6184-6194 (2002).
122. O'Connell, M. J., Krien, M. J. & Hunter, T. Never say never. The NIMA-related protein kinases in mitotic control. Trends Cell Biol. 13, 221-228 (2003).
123. Andersen, J. S. et al. Proteomic characterization of the human centrosome by protein correlation profiling. Nature 426, 570-574 (2003).
124. Tokuyama, Y., Horn, H. F., Kawamura, K., Tarapore, P. & Fukasawa, K. Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J. Biol. Chem. 276, 21529-21537 (2001).
125. Okuda, M. The role of nucleophosmin in centrosome duplication. Oncogene 21, 6170-6174 (2002).
126. Liu, X. & Erikson, R. L. Polo-like kinase 1 in the life and death of cancer cells. Cell Cycle 2, 424-425 (2003).
127. Wu-Baer, F., Lagrazon, K., Yuan, W. & Baer, R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 278, 34743-34746 (2003).
128. Nishikawa, H. et al. Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J. Biol. Chem. 279, 3916-3924 (2004).
129. Sato, K. et al. Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J. Biol. Chem. 279, 30919-30922 (2004).
130. Xu, X. et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3, 389-395 (1999).
131. Saavedra, H. I. et al. Inactivation of E2F3 results in centrosome amplification. Cancer Cell 3, 333-346 (2003).
132. Bernard, K. et al. Functional proteomic analysis of melanoma progression. Cancer Res. 63, 6716-6725 (2003).
133. Di Fiore, B., Ciciarello, M. & Lavia, P. Mitotic functions of the Ran GTPase network: the importance of being in the right place at the right time. Cell Cycle 3, 305-313 (2004).
134. Dasso, M. Running on Ran: nuclear transport and the mitotic spindle. Cell 104, 321-324 (2001).
135. Forgues, M. et al. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol. Cell. Biol. 23, 5282-5292 (2003).
136. Keryer, G. et al. Part of Ran is associated with AKAP450 at the centrosome: involvement in microtubule-organizing activity. Mol. Biol. Cell 14, 4260-4271 (2003).
137. Wang, W., Budhu, A., Forgues, M. & Wang, X. W. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nature Cell Biol. 7, 823-830 (2005). The RAN-CRM1 network is involved in the regulation of centrosome duplication and proper formation of a bipolar spindle. NPM is proposed to be a RAN-CRM1 substrate in the control of centrosome duplication.
138. Shinmura, K., Tarapore, P., Tokuyama, Y., George, K. R. & Fukasawa, K. Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity. FEBS Lett. 579, 6621-6634 (2005).
139. Budhu, A. S. & Wang, X. W. Loading and unloading: orchestrating centrosome duplication and spindle assembly by Ran/Crm1. Cell Cycle 4, 1508-1512 (2005).
140. Brunning, R.D. et al. in Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues CH.3 (eds Jaffe, E. S. et al.) 91-105 (IARC, Lyon, France, 2001).
141. Nishimura, Y., Ohkubo, T., Furuichi, Y. & Umekawa, H. Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci. Biotechnol. Biochem. 66, 2239-2242 (2002).
142. Duyster, J., Bai, R. Y. & Morris, S. W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20, 5623-5637 (2001).
143. Falini, B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br. J. Haematol. 114, 741-760 (2001).
144. Grimwade, D. et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action 'Molecular Cytogenetic Diagnosis in Haematological Malignancies'. Blood 96, 1297-1308 (2000).
145. Redner, R. L. Variations on a theme: the alternate translocations in APL. Leukemia 16, 1927-1932 (2002).
146. Cazzaniga, G. et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 106, 1419-1422 (2005).